Is Opdivo + Chemotherapy Effective for Lung Cancer?
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
On August 10, 2023, Mariano Provencio and colleagues from Puerta de Hierro University published the results of a Phase 2 clinical trial in "The New England Journal of Medicine." The study evaluated the efficacy and safety of neoadjuvant Opdivo plus platinum-based chemotherapy in patients with Stage IIIA/IIIB non-small cell lung cancer (NSCLC).
This open-label Phase 2 trial randomized patients with Stage IIIA/IIIB NSCLC (N=86) to receive either Opdivo + chemotherapy (N=57) or chemotherapy alone (N=29). The primary endpoint was pathological complete response (pCR) rate, and secondary endpoints included progression-free survival (PFS) and overall survival (OS).
The results showed that the pCR rate was 37% in the Opdivo + chemotherapy group compared to 7% in the chemotherapy group. The surgical resection rate was 93% in the Opdivo + chemotherapy group versus 69% in the chemotherapy group.
For secondary endpoints, the 24-month PFS rate was 67.2% in the Opdivo + chemotherapy group compared to 40.9% in the chemotherapy group. The 24-month OS rate was 85% in the Opdivo + chemotherapy group versus 63.6% in the chemotherapy group.
Regarding safety, the incidence of Grade 3-4 adverse events was 19% in the Opdivo + chemotherapy group and 10% in the chemotherapy group.
Based on the Phase 2 results, Mariano Provencio stated that neoadjuvant Opdivo plus platinum-based chemotherapy improved pCR rate, PFS, and OS in patients with Stage IIIA/IIIB NSCLC.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4